Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice.
OBJECTIVE
There has been a revolution in cardiovascular neuroscience in recent years with, in some cases, translation into clinical practice of the knowledge of pathophysiology gained through application of sympathetic nerve recording and catecholamine isotope dilution methodology. OBESITY-RELATED HYPERTENSION: An earlier hypothesis, based on findings in most models, was that weight gain in obesity is due in part to sympathetic nervous underactivity reducing thermogenesis. Microneurography and regional noradrenaline spillover measurements in human obesity have disproven this hypothesis, weakening the case for the use of beta3-adrenergic agonists to stimulate thermogenesis. Sympathetic nerve firing rates in post-ganglionic fibres directed to the skeletal muscle vasculature are increased, as is renal sympathetic tone, with a doubling of the spillover rate of noradrenaline from the kidneys. Given these findings, antiadrenergic antihypertensive drugs may be the preferred agents for obesity-related hypertension, but this has not been adequately tested.
Whether stress causes high blood pressure, previously hotly debated, has been under recent review by an Australian Government body, the Specialist Medical Review Council. Despite medicolegal implications, the ruling was that stress is one proven cause of hypertension. The judgment was reached after consideration of the epidemiological evidence, but in particular the described neural pathophysiology of essential hypertension: (a) persistent sympathetic nervous stimulation is commonly present, (b) suprabulbar projections of noradrenergic brainstem neurones are activated and (c) adrenaline is released as a cotransmitter in sympathetic nerves. These were taken to be biological markers of stress.
At one time, the failing heart was thought to be sympathetically denervated. Longterm administration of inotropic adrenergic agonists, to provide the cardiac catecholamine stimulation thought to be lacking, increased mortality. Noradrenaline isotope dilution methodology subsequently demonstrated that the sympathetic outflow to the heart was preferentially activated, cardiac noradrenaline spillover being increased as much as 50-fold. The level of stimulation of the cardiac sympathetic nerves was the most powerful predictor of death. These observations provide the theoretical foundation for the very successful introduction of beta-adrenergic blockers for treatment of heart failure.
Esler
M
M
Baker Heart Research Institute, Prahran, Melbourne, Australia.
Lambert
G
G
Brunner-La Rocca
H P
HP
Vaddadi
G
G
Kaye
D
D
D001342:Autonomic Nervous System Diseases / Q000150:complications / Q000188:drug therapy; D002303:Cardiac Output, Low / Q000188:drug therapy / Q000503:physiopathology*; D002395:Catecholamines; D004299:Dopamine beta-Hydroxylase / Q000172:deficiency; D004594:Electrophysiology / Q000379:methods; D004837:Epinephrine / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D008839:Microelectrodes; D009474:Neurons / Q000502:physiology; D018377:Neurotransmitter Agents / Q000502:physiology*; D009638:Norepinephrine / Q000502:physiology; D009765:Obesity / Q000188:drug therapy / Q000503:physiopathology*; D013315:Stress, Psychological / Q000150:complications; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D013569:Synapses / Q000502:physiology
D002395:Catecholamines; D018377:Neurotransmitter Agents; D004299:Dopamine beta-Hydroxylase; D009638:Norepinephrine; D004837:Epinephrine